Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses
© 2021 The Author(s)..
Type I interferons (IFNs) are our first line of defense against virus infection. Recent studies have suggested the ability of SARS-CoV-2 proteins to inhibit IFN responses. Emerging data also suggest that timing and extent of IFN production is associated with manifestation of COVID-19 severity. In spite of progress in understanding how SARS-CoV-2 activates antiviral responses, mechanistic studies into wild-type SARS-CoV-2-mediated induction and inhibition of human type I IFN responses are scarce. Here we demonstrate that SARS-CoV-2 infection induces a type I IFN response in vitro and in moderate cases of COVID-19. In vitro stimulation of type I IFN expression and signaling in human airway epithelial cells is associated with activation of canonical transcriptions factors, and SARS-CoV-2 is unable to inhibit exogenous induction of these responses. Furthermore, we show that physiological levels of IFNα detected in patients with moderate COVID-19 is sufficient to suppress SARS-CoV-2 replication in human airway cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
iScience - 24(2021), 5 vom: 21. Mai, Seite 102477 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Banerjee, Arinjay [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.06.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.isci.2021.102477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM324908318 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM324908318 | ||
| 003 | DE-627 | ||
| 005 | 20231225191317.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2021.102477 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1082.xml |
| 035 | |a (DE-627)NLM324908318 | ||
| 035 | |a (NLM)33937724 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Banerjee, Arinjay |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.06.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 The Author(s). | ||
| 520 | |a Type I interferons (IFNs) are our first line of defense against virus infection. Recent studies have suggested the ability of SARS-CoV-2 proteins to inhibit IFN responses. Emerging data also suggest that timing and extent of IFN production is associated with manifestation of COVID-19 severity. In spite of progress in understanding how SARS-CoV-2 activates antiviral responses, mechanistic studies into wild-type SARS-CoV-2-mediated induction and inhibition of human type I IFN responses are scarce. Here we demonstrate that SARS-CoV-2 infection induces a type I IFN response in vitro and in moderate cases of COVID-19. In vitro stimulation of type I IFN expression and signaling in human airway epithelial cells is associated with activation of canonical transcriptions factors, and SARS-CoV-2 is unable to inhibit exogenous induction of these responses. Furthermore, we show that physiological levels of IFNα detected in patients with moderate COVID-19 is sufficient to suppress SARS-CoV-2 replication in human airway cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Virology | |
| 700 | 1 | |a El-Sayes, Nader |e verfasserin |4 aut | |
| 700 | 1 | |a Budylowski, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Jacob, Rajesh Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Richard, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Maan, Hassaan |e verfasserin |4 aut | |
| 700 | 1 | |a Aguiar, Jennifer A |e verfasserin |4 aut | |
| 700 | 1 | |a Demian, Wael L |e verfasserin |4 aut | |
| 700 | 1 | |a Baid, Kaushal |e verfasserin |4 aut | |
| 700 | 1 | |a D'Agostino, Michael R |e verfasserin |4 aut | |
| 700 | 1 | |a Ang, Jann Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Murdza, Tetyana |e verfasserin |4 aut | |
| 700 | 1 | |a Tremblay, Benjamin J-M |e verfasserin |4 aut | |
| 700 | 1 | |a Afkhami, Sam |e verfasserin |4 aut | |
| 700 | 1 | |a Karimzadeh, Mehran |e verfasserin |4 aut | |
| 700 | 1 | |a Irving, Aaron T |e verfasserin |4 aut | |
| 700 | 1 | |a Yip, Lily |e verfasserin |4 aut | |
| 700 | 1 | |a Ostrowski, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Hirota, Jeremy A |e verfasserin |4 aut | |
| 700 | 1 | |a Kozak, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Capellini, Terence D |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Mubareka, Samira |e verfasserin |4 aut | |
| 700 | 1 | |a McGeer, Allison J |e verfasserin |4 aut | |
| 700 | 1 | |a McArthur, Andrew G |e verfasserin |4 aut | |
| 700 | 1 | |a Doxey, Andrew C |e verfasserin |4 aut | |
| 700 | 1 | |a Mossman, Karen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t iScience |d 2018 |g 24(2021), 5 vom: 21. Mai, Seite 102477 |w (DE-627)NLM285332627 |x 2589-0042 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2021 |g number:5 |g day:21 |g month:05 |g pages:102477 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.isci.2021.102477 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2021 |e 5 |b 21 |c 05 |h 102477 | ||